Who: Takeda, CSL Behring, Octapharma, Biotest, Bio Products Laboratory, LFB Biotechnologies
What: Six companies will combine their expertise and resources to develop a plasma-derived therapy for patients with serious complications of...
Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy
Listen to this article
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Keep up with the top pharma business news of the week. On the go.
More from COVID-19
• By
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
• By
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
• By
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
• By
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains